Loading company…
Signadori Bio is developing engineered monocyte therapies for solid tumors.
Signadori Bio develops p21-engineered monocytes intended to enhance immune responses against solid tumors. The company was founded in 2025 in Paris, France, by Jean-Luc Perfettini and Nathalie Chaput; Selwyn Ho was CEO as of June 2026. It raised Seed funding in May 2026, co-led by Taiho Ventures, Sofinnova Partners, and Invivo Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in